CAITLIN WILLSIE: Open Payments
NPI 1093209686 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$513 in 29 payments from 14 companies in 2025. Trend: 2023 $537 · 2024 $483 · 2025 $513
Food & beverage: $513
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $81 |
| Dexcom, Inc. | 4 | $78 |
| Astellas Pharma US Inc | 4 | $57 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $52 |
| Novo Nordisk Inc | 2 | $40 |
| SHIELD THERAPEUTICS INC | 2 | $37 |
| ABBVIE INC. | 2 | $34 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $29 |
| Exact Sciences Corporation | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
Products named: AIRSUPRA, Dexcom G6 Transmitter, Veozah, JARDIANCE, ACCRUFER, QULIPTA, XIFAXAN, Ozempic.
Industry payments across LA — which companies pay providers there.
